Laserfiche WebLink
DocuSign Envelope ID:040056EC-0D41-4D98-9C65-E01AE876A6AB <br /> workers or other school staff, to address mental health needs in young people that <br /> (when not properly addressed) increase the risk of opioid or another drug misuse. <br /> H. PREVENT OVERDOSE DEATHS AND OTHER HARMS (HARM REDUCTION) <br /> Support efforts to prevent or reduce overdose deaths or other opioid-related harms <br /> through evidence-based or evidence-informed programs or strategies that may include, <br /> but are not limited to, the following: <br /> 1. Increased availability and distribution of naloxone and other drugs that treat <br /> overdoses for first responders, overdose patients, individuals with OUD and their <br /> friends and family members, schools, community navigators and outreach <br /> workers, persons being released from jail or prison, or other members of the <br /> general public. <br /> 2. Public health entities providing free naloxone to anyone in the community. <br /> 3. Training and education regarding naloxone and other drugs that treat overdoses <br /> for first responders, overdose patients,patients taking opioids, families, schools, <br /> community support groups, and other members of the general public. <br /> 4. Enabling school nurses and other school staff to respond to opioid overdoses, and <br /> provide them with naloxone, training, and support. <br /> 5. Expanding, improving, or developing data tracking software and applications for <br /> overdoses/naloxone revivals. <br /> 6. Public education relating to emergency responses to overdoses. <br /> 7. Public education relating to immunity and Good Samaritan laws. <br /> 8. Educating first responders regarding the existence and operation of immunity and <br /> Good Samaritan laws. <br /> 9. Syringe service programs and other evidence-informed programs to reduce harms <br /> associated with intravenous drug use, including supplies, staffing, space, peer <br /> support services, referrals to treatment, fentanyl checking, connections to care, <br /> and the full range of harm reduction and treatment services provided by these <br /> programs. <br /> 10. Expanding access to testing and treatment for infectious diseases such as HIV and <br /> Hepatitis C resulting from intravenous opioid use. <br /> 11. Supporting mobile units that offer or provide referrals to harm reduction services, <br /> treatment, recovery supports, health care, or other appropriate services to persons <br /> that use opioids or persons with OUD and any co-occurring SUD/MH conditions. <br /> 10 <br />